{Reference Type}: Journal Article
{Title}: HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families.
{Author}: Janakiram M;Chinai JM;Zhao A;Sparano JA;Zang X;
{Journal}: Oncoimmunology
{Volume}: 4
{Issue}: 8
{Year}: Aug 2015
暂无{DOI}: 10.1080/2162402X.2015.1026534
{Abstract}: We and others recently discovered HHLA2 as a new B7 family member and transmembrane and immunoglobulin domain containing 2 (TMIGD2) as one of its receptors. Based on a new study we propose that HHLA2 may represent a novel immunosuppressive mechanism within the tumor microenvironment and hence could be a target for cancer therapy. TMIGD2 may be another therapeutic target.